journal article·2017-09-07

Enhanced Efficiency of 13C Dynamic Nuclear Polarization by Superparamagnetic Iron Oxide Nanoparticle Doping

Peter Niedbalski, Christopher R. Parish, Qing Wang, Zahra Hayati, Likai Song, Zackary I. Cleveland, Lloyd Lumata

The Journal of Physical Chemistry C· Volume 121· Issue 35
Publisher page

Abstract

The attainment of high NMR signal enhancements is crucial to the success of in vitro or in vivo hyperpolarized NMR or imaging (MRI) experiments. In this work, we report on the use of a superparamagnetic iron oxide nanoparticle (SPION) MRI contrast agent Feraheme (ferumoxytol) as a beneficial additive in 13 C samples for dissolution dynamic nuclear polarization (DNP). Our DNP data at 3.35 T and 1.2 K reveal that the addition of 11 mM elemental iron concentration of Feraheme in trityl OX063-doped 3 M [1- 13 C] acetate samples resulted in a substantial improvement of 13 C DNP signal by a factor of almost three-fold. Concomitant with the large DNP signal increase is the narrowing of the 13 C microwave DNP spectra for samples doped with SPION. W-band electron paramagnetic resonance (EPR) spectroscopy data suggest that these two prominent effects of SPION doping on 13 C DNP can be ascribed to the shortening of trityl OX063 electron T 1, as explained within the thermal mixing DNP model. Liquid-state 13 C NMR signal enhancements as high as 20,000-fold for SPION-doped samples were recorded after dissolution at 9.4 T and 297 K, which is about three times the liquid-state NMR signal enhancement of the control sample. While the presence of SPION in hyperpolarized solution drastically reduces 13 C T 1, this can be mitigated by polarizing smaller aliquots of DNP samples. Moreover, we have shown that Feraheme nanoparticles (∼30 nm in size) can be easily and effectively removed from the hyperpolarized liquid by simple mechanical filtration, and thus one can potentially incorporate an in-line filtration for these SPIONS along the dissolution pathway of the hyperpolarizer, a significant advantage over other DNP enhancers such as the lanthanide complexes. The overall results suggest that the commercially available and FDA-approved Feraheme is a highly efficient DNP enhancer that could be readily translated for use in clinical applications of dissolution DNP.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced NMR Techniques and Applications · Solid-state spectroscopy and crystallography · Electron Spin Resonance Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Physics, University of Texas at Dallas, 800 West Campbell Road, Richardson, Texas 75080 United States

National High Magnetic Field Laboratory, Florida State University, 1800 East Paul Dirac Drive, Tallahassee, Florida 32310, United States

Center for Pulmonary Imaging Research, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio 45229, United States

Department of Biomedical Engineering, University of Cincinnati, Cincinnati, Ohio 45221, United States

Funding

Welch Foundation · National Heart, Lung, and Blood Institute · U.S. Department of Defense · Division of Materials Research · State of Florida

References (61)

Show source-provided references
1. 10.1088/0034-4885/41/3/00210.1088/0034-4885/41/3/002 ↗
2. 10.1146/annurev.nucl.47.1.6710.1146/annurev.nucl.47.1.67 ↗
3. 10.1088/1742-6596/324/1/01200310.1088/1742-6596/324/1/012003 ↗
4. 10.1007/BF0065522110.1007/BF00655221 ↗
5. 10.1007/s00723-008-0111-y10.1007/s00723-008-0111-y ↗
6. 10.1039/c0cp90019b10.1039/c0cp90019b ↗
7. 10.1073/pnas.173383510010.1073/pnas.1733835100 ↗
8. 10.1016/j.nima.2004.03.17110.1016/j.nima.2004.03.171 ↗
9. 10.1038/srep0910410.1038/srep09104 ↗
10. 10.1007/s00723-012-0335-810.1007/s00723-012-0335-8 ↗
11. 10.1002/anie.20110607310.1002/anie.201106073 ↗
12. 10.1016/j.pnmrs.2009.06.00110.1016/j.pnmrs.2009.06.001 ↗
13. 10.1007/s00723-012-0336-710.1007/s00723-012-0336-7 ↗
14. 10.1016/j.jmr.2015.12.02710.1016/j.jmr.2015.12.027 ↗
15. 10.1002/mrm.2299910.1002/mrm.22999 ↗
16. 10.1038/nm165010.1038/nm1650 ↗
17. 10.1593/neo.10110210.1593/neo.101102 ↗
18. 10.1038/nm.341610.1038/nm.3416 ↗
19. 10.2967/jnumed.114.14170510.2967/jnumed.114.141705 ↗
20. 10.1002/mrm.2541910.1002/mrm.25419 ↗
21. 10.1016/j.molcel.2014.09.02510.1016/j.molcel.2014.09.025 ↗
22. 10.1016/bs.mie.2015.04.00610.1016/bs.mie.2015.04.006 ↗
23. 10.1002/nbm.168210.1002/nbm.1682 ↗
24. 10.1126/scitranslmed.300607010.1126/scitranslmed.3006070 ↗
25. 10.1016/j.cplett.2011.10.04210.1016/j.cplett.2011.10.042 ↗
26. 10.1002/cmmi.147410.1002/cmmi.1474 ↗
27. 10.1088/0031-9155/56/5/N0110.1088/0031-9155/56/5/N01 ↗
28. 10.1039/c3cp50750e10.1039/c3cp50750e ↗
29. 10.1002/mrc.459710.1002/mrc.4597 ↗
30. 10.1002/mrc.462410.1002/mrc.4624 ↗
31. 10.1007/s10334-014-0455-210.1007/s10334-014-0455-2 ↗
32. 10.1007/s00723-008-0134-410.1007/s00723-008-0134-4 ↗
33. 10.1002/chem.20110203710.1002/chem.201102037 ↗
34. 10.1016/j.jmr.2012.11.00610.1016/j.jmr.2012.11.006 ↗
35. 10.1021/jp302399f10.1021/jp302399f ↗
36. 10.1039/c3cp50186h10.1039/c3cp50186h ↗
37. 10.1039/c2ra21853d10.1039/c2ra21853d ↗
38. 10.1016/j.cplett.2012.08.01710.1016/j.cplett.2012.08.017 ↗
39. 10.1002/mrc.448010.1002/mrc.4480 ↗
40. 10.1021/acs.jpca.7b0184410.1021/acs.jpca.7b01844 ↗
41. 10.1016/j.jmr.2016.01.01510.1016/j.jmr.2016.01.015 ↗
42. 10.1016/j.nima.2010.10.15610.1016/j.nima.2010.10.156 ↗
43. 10.1002/mrm.2420710.1002/mrm.24207 ↗
44. 10.1039/C6CP03954E10.1039/C6CP03954E ↗
45. 10.1039/C6RA02864K10.1039/C6RA02864K ↗
46. 10.1063/1.497331710.1063/1.4973317 ↗
47. 10.1021/acs.jpca.7b0386910.1021/acs.jpca.7b03869 ↗
48. 10.1002/cmmi.14610.1002/cmmi.146 ↗
49. 10.1002/jmri.2469110.1002/jmri.24691 ↗
50. 10.1158/1078-0432.CCR-10-342010.1158/1078-0432.CCR-10-3420 ↗
51. 10.3390/ijms14091750110.3390/ijms140917501 ↗
52. 10.1007/s10534-015-9845-910.1007/s10534-015-9845-9 ↗
53. 10.1111/j.1365-2362.2009.02130.x10.1111/j.1365-2362.2009.02130.x ↗
54. 10.1063/1.134664010.1063/1.1346640 ↗
55. 10.1039/C4CP02013H10.1039/C4CP02013H ↗
56. 10.1021/ja201880y10.1021/ja201880y ↗
57. 10.1007/s00723-008-0117-510.1007/s00723-008-0117-5 ↗
58. 10.1103/PhysRevB.74.13441810.1103/PhysRevB.74.134418 ↗
59. 10.1016/j.nima.2004.03.14710.1016/j.nima.2004.03.147 ↗
60. 10.1103/PhysRevLett.20.41910.1103/PhysRevLett.20.419 ↗
61. 10.1016/j.jmr.2017.01.02010.1016/j.jmr.2017.01.020 ↗